Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians

Diabet Med. 2006 May;23(5):537-43. doi: 10.1111/j.1464-5491.2006.01843.x.

Abstract

Aims: To determine the effects of pioglitazone (30 mg once daily for 16 weeks) on insulin sensitivity, insulin-mediated vasodilation, vascular inflammatory markers, fat distribution and lipids in Asian Indians and Caucasians of European ancestry.

Methods: Cross-sectional study. Eighteen non-diabetic Asian Indians and 17 Caucasians of comparable age (34 +/- 3 vs. 36 +/- 3 years) and body mass index (26.0 +/- 1.2 vs. 24.7 +/- 1.0 kg/m(2)) had measurements of insulin sensitivity (M, insulin clamp at 6 pmol/kg per min), abdominal fat (computed tomographic scan at L4-L5), endothelial-dependent (reactive hyperaemia, RH) and -independent (0.4 mg sublingual nitroglycerin, TNG) vasodilation using brachial artery ultrasound before and after the 2-h clamp at baseline and after pioglitazone therapy.

Results: Asian Indians were insulin resistant compared with Causasians during the baseline clamp (M = 25.6 +/- 1.7 vs. 41.1 +/- 2.2 micromol/kg per min, P < 0.0001) and improved significantly after pioglitazone (to 33.9 +/- 1.7 micromol/kg per min, P < 0.001). Vasodilatory responses to RH and TNG were similar in Asian Indians and Caucasians at baseline and did not change. Insulin-mediated vasodilation improved after pioglitazone in Asian Indians, but not in Caucasians, and correlated with the change in insulin sensitivity (r = 0.52, P = 0.03). C-reactive protein (CRP) was higher in Asian Indians vs. Caucasians (1.6 +/- 0.4 vs. 0.9 +/- 0.2 mg/l) and was negatively correlated with insulin sensitivity (r = -0.53, P = 0.02). In the Asian Indian group, CRP and plasminogen activator inhibitor-1 decreased and adiponectin increased after pioglitazone, but there were no significant changes in total or visceral fat.

Conclusions: These results demonstrate that insulin-resistant Asian Indians respond favourably to an insulin sensitizer with improvements in insulin sensitivity, cardiovascular and inflammatory risk markers, and vascular responses to insulin. These agents may have a role in decreasing the risk of diabetes and cardiovascular disease in this high-risk population.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects*
  • Administration, Sublingual
  • Adult
  • Aged
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Brachial Artery / drug effects
  • Cardiovascular Diseases / metabolism
  • Cross-Sectional Studies
  • Drug Administration Schedule
  • Endothelium, Vascular / drug effects
  • Female
  • Glucose Clamp Technique / methods
  • Humans
  • Hyperemia / metabolism
  • Hypoglycemic Agents / administration & dosage*
  • India / ethnology
  • Insulin / blood
  • Insulin Resistance / physiology*
  • Lipids / blood
  • Male
  • Middle Aged
  • Nitroglycerin / administration & dosage
  • Pioglitazone
  • Risk Factors
  • Thiazolidinediones / administration & dosage*
  • United States / epidemiology
  • Vasodilation / drug effects*
  • Vasodilator Agents / administration & dosage

Substances

  • Biomarkers
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Lipids
  • Thiazolidinediones
  • Vasodilator Agents
  • Nitroglycerin
  • Pioglitazone